---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-031138"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T21:32:31.543596+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa reports Q4 2023 net loss $33.3M; cash into H1 2026; key pipeline milestones on track

## Summary
- Net loss Q4 2023 $33.3M ($30.8M prior year); FY net loss $135.4M; cash $237M, runway into H1 2026.
- MRT-2359 MYC-driven solid tumors Phase 1/2; recommended Phase 2 dose expected Q2 2024; Fast Track for SCLC and NSCLC.
- MRT-6160 VAV1 MGD IND filing planned Q2 2024; Phase 1 SAD/MAD study start mid-2024.
- MRT-8102 NEK7 program first development candidate nominated; IND submission targeted Q1 2025.
- Entered Roche collaboration; $50M upfront, potential >$2B milestones plus royalties.

## SEC filing metadata
- accession: 0000950170-24-031138
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017024031138/0000950170-24-031138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017024031138/glue-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-031138
- JSON: https://secwatch.observer/filing/0000950170-24-031138.json
- Plain text: https://secwatch.observer/filing/0000950170-24-031138.txt

## Key facts
- Earnings Releases
  Monte Rosa Therapeutics, Inc. reported financial results for full year and fourth quarter ended December 31, 2023.
  - Period: full year and fourth quarter ended December 31, 2023
  - Result: reported results
  source text: Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000095017024031138/0000950170-24-031138-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.